Contact Us
Pay Invoice
Follow Us!
Latest Blogs
- Latest CDC Findings: A Wake‑Up Call for the $1.3 Billion Global Sepsis Diagnostics Market April 6, 2026
- NAMs, NIH Policy, and What it Means for Diagnostics March 20, 2026
- As Flu Outpaces COVID This Winter, Rapid Molecular Testing Takes on New Importance March 17, 2026
- March Is Colorectal Cancer Awareness Month: How Liquid Biopsy Is Shaping the Future of CRC Detection and Care February 20, 2026
- Global IVD Growth: Stability, Shifting Markets, and the Road to 2030 February 11, 2026
Sitemap
Your Data and Privacy
About Us
Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.
Visit Science and Medicine Group
Visit Science and Medicine Group
COVID-19: A Vaccine Solution?
Not since the Swine Flu epidemic of 2009 has there been this amount of emphasis on vaccines and vaccine development. This new infectious disease threat with no anti-viral, nor vaccine is causing significant concern among healthcare providers, governments and the public. Last-resort measures such as school closings and curfews in place in the United States […]
White House COVID-19 Plan Contains Diagnostics Boost
A rapid scale-up of diagnostic testing for the novel coronavirus was the focus of a declaration of emergency by President Donald Trump in a March 13 press conference. The plan calls for sharply boosting the production of coronavirus test kits while also making tests available at a network of drive-through sites. In an address at the […]
Slower-Than-Expected Adoption of Molecular Point-of-Care, But Growth Comes from Consumables
Molecular point-of-care diagnostic solutions offer improvements in the sensitivity and specificity of existing near-patient and rapid tests while expanding the diagnostic capabilities at points of care, such as hospital critical care units, physician offices, outpatient clinics, and community health posts in the developing world, and are used to assess conditions or admit patients. The concept […]
Revival of VALID Act Draws Mixed Response
March 9, 2020 — The revival of legislation to change the regulation of laboratory-developed tests (LDTs) has drawn a mixed response. The reintroduction of the Verifying Accurate, Leading-edge IVCT Development (VALID) Act is intended to remove barriers that are believed to have impeded the U.S. government’s response to the coronavirus epidemic. The issue of diagnostics […]
Boost for Remote Patient Monitoring in COVID-19 Bill That Passed House, Senate
The House of Representatives and Senate today passed an $8.3 billion spending package to help providers and local governments handle the spread of the coronavirus and to boost the development of vaccines and tests of the virus. While vaccine support and spending on healthcare is expected, the bill also boosts telehealth solutions with financial support […]
Coronavirus Mortality Rate Upped to 3.4%; Increasing Need for Testing
With the world’s major health organization upping the mortality rate to 3.4%, there is increased need for a working rapid test for COVID-19 to be able to properly isolate patients and protect providers. The World Health Organization (WHO) has raised its estimate of the mortality rate of patients infected with the novel coronavirus to 3.4% […]
Thermo Fisher set to acquire Qiagen after all in $11.5B deal
Courtesy of LabPulse.com March 3, 2020 — After an on-and-off courtship, Thermo Fisher Scientific announced it is set to acquire Qiagen in a deal worth $11.5 billion. The transaction will give Thermo Fisher access to Qiagen’s molecular diagnostics expertise and potentially lead to faster development of diagnostic tests. The deal values Qiagen at 39 euros ($44) per […]
Expect to Hear a Lot of Talk about Coronavirus and Molecular Point of Care
A Harvard Business Review article calls for molecular point of care to step in to detect #coronavirus. You’ll hear a lot of this in coming weeks, we think. Molecular point of care is less than 10 years old but has shown promise in flu/strep, other respiratory pathogens. They are in the right place at the right […]
Molecular Diagnostics for Cancer Grows, Fueled by NGS-based Testing
Cancer diagnostics is a highly dynamic field that consists of various types of platforms. Molecular diagnostics platforms are increasingly becoming popular as they enable accurate diagnosis as well as prognosis evaluation, which are important for treatment decisions. In 2019, the market for molecular cancer diagnostics, including histology and assays, reached $1,600 million, increasing 11.5% over […]
Clinical Labs are a 120+ Billion-Dollar Industry Globally
The global market for clinical laboratory services is estimated at $121.5 billion for 2019. This is up 2.9% from the estimated value in 2010 of $93.9 billion, according to a new Kalorama Information report. (https://kaloramainformation.com/product/clinical-laboratory-services-market-5th-edition/ ) Growth is driven by an aging population, a growing incidence of chronic diseases, but it is more than that. The […]